Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ryan Hermansen

Physician Assistant, Medical Salem, OR Physician Assistant

NPI 1831681618 CMS profile 10725965

610 Hawthorne Ave Se Ste 110, Salem, OR 97301

Open in the dashboard

General payments

$3,621

152 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Hermansen of Salem, OR is reported in the CMS Open Payments database as having received $3,621 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $270 3
2024 General $180 3
2023 General $149 3
2022 General $1,299 60
2021 General $1,724 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Hermansen
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ryan Hermansen were reported at $270. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ryan Hermansen Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,724 $156 $41–$563 $132
2022 $1,299 $185 $55–$649 $149
2023 $149 $199 $58–$717 $160
2024 $180 $206 $62–$740 $164
2025 $270 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $639 8 payments
  2. Novartis Pharmaceuticals Corporation $470 31 payments
  3. Boston Scientific Corporation $392 8 payments
  4. Amgen Inc. $260 12 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $208 10 payments
  6. CMP Pharma, Inc. $203 7 payments
  7. Merck Sharp & Dohme Corporation $197 9 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $175 5 payments
  9. Janssen Pharmaceuticals, Inc $168 14 payments
  10. Esperion Therapeutics, Inc. $162 10 payments
  11. Other $748 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,408 148 payments
  2. Education $213 4 payments
Products named General payments · program years 2021–2025
  1. ENTRESTO $419 28 payments
  2. BRILINTA $315 3 payments
  3. Repatha $260 12 payments
  4. FARXIGA $225 4 payments
  5. JARDIANCE $208 10 payments
  6. CaroSpir $203 7 payments
  7. VERQUVO $197 9 payments
  8. Kerendia $175 5 payments
  9. XARELTO $168 14 payments
  10. NEXLETOL $162 10 payments
  11. Other $1,256 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,264

Median for Physician Assistant: 241

Drug cost

$395,151

Median for Physician Assistant: $4,110

Branded share of claims

36.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 197 $273,263
Xarelto Rivaroxaban Brand 59 $83,697
Flecainide Acetate Generic 251 $11,318
Dofetilide Generic 45 $11,197
Metoprolol Succinate Generic 256 $4,198
Sotalol Sotalol Hcl Brand 166 $2,747
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 11 $2,441
Amiodarone Hcl Generic 117 $2,252
Mexiletine Hcl Generic 11 $2,251
Dilt-Xr Diltiazem Hcl Brand 17 $590

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$40,380

Medicare's payments for the services billed

Medicare patients

331

Average age 75

Services billed

638

147 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 50%
Ischemic heart disease 38%
Arthritis 38%
Chronic kidney disease 29%
Diabetes 24%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record